查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1392121

骨髓增生性肿瘤 (MPN) 治疗市场：按疾病类型、按药物类别、按配销通路、按地区

Myeloproliferative Neoplasms Treatment Market, By Disease Type, By Drug Class, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 180 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到 2023 年，全球骨髓增生性肿瘤 (MPN) 治疗市场将达到 94 亿美元，预测期内（2023-2030 年）复合年增长率为 3.9%。

报告范围 报告详情
基准年 2022年 2023年市场规模 94亿美元
实绩资料 2018-2021 预测期 2023-2030
预测期复合年增长率 3.90% 2030年市场规模预测 122.8亿美元
图 1. 2023 年按疾病类型分類的骨髓增生性肿瘤 (MPN) 治疗的全球市场占有率(%)
骨髓增生性肿瘤治疗市场-IMG1

骨髓增生性肿瘤（MPN）是一组罕见的骨髓疾病，会导致血球数量增加。与骨髓增生性肿瘤 (MPN) 相关的症状包括频繁头痛、疲劳、瘀伤或异常出血、视力模糊、耳鸣以及眼部问题（例如比平常更具传染性）。此外，骨髓增生性肿瘤（MPN）的诊断需要进行血液检查，该检查可以显示血球的数量并可以检查基因突变。还可以进行其他检查，例如骨髓检查和腹部超音波。

市场动态

骨髓增生性肿瘤（MPN）治疗产业的主要参与者正在专注于研究和开发，以开发骨髓增生性肿瘤（MPN）的创新治疗方法。因此，市场研发活动的增加预计将在预测期内推动全球骨髓增生性肿瘤（MPN）治疗市场的成长。例如，2023 年 2 月 23 日，PharmaEssentia 总公司是一家总部位于台湾的全球生物製药创新公司，利用深厚的专业知识和经过验证的科学原理，在血液学和肿瘤学领域提供新型生技药品。PharmaEssentia USA Corporation是PharmaEssentia USA Corporation 的子公司，宣布第一位患者已开始在一项2B 期临床试验中给药，该试验评估了rodeginterferon alfa-2b-njft 用于治疗成人原发性血小板增多症(ET) 的效果。 BESREMi（ropeginterferon alfa-2b-njft）是一种创新的单聚乙二醇化长效干扰素。 BESREMi由于其独特的聚乙二醇化技术，在体内的活性持续时间较长，可以每两週给药一次（如果血液学稳定超过一年则可以每四周给药一次），可根据患者的个体需要灵活给药。患者。

本次测试的主要特点

  • 本报告对全球骨髓增生性肿瘤（MPN）治疗药物市场进行了详细分析，并列出了以2022年为基准年的预测期（2023-2030年）的市场规模和復合年增长率。它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
  • 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
  • 根据公司亮点、产品系列、主要亮点、绩效和策略等参数，对全球骨髓增生性肿瘤 (MPN) 治疗市场的主要企业进行了分析。
  • 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
  • 全球骨髓增生性肿瘤 (MPN) 治疗市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
  • 透过用于分析全球骨髓增生性肿瘤（MPN）治疗的各种策略矩阵，将有助于相关人员做出决策。

目录

第1章研究目的与前提

  • 研究目标
  • 假设
  • 简称

第2章市场展望

  • 报告说明
    • 市场定义和范围
  • 执行摘要
  • Coherent Opportunity Map（COM）

第3章市场动态、法规及趋势分析

  • 市场动态
    • 促进因素
    • 抑制因素
    • 市场机会
  • 影响分析
  • 监管场景
  • 流行病学
  • 合併、收购和合作
  • 监管场景
  • 主要进展
  • PEST分析

第4章全球骨髓增生性肿瘤（MPN）治疗市场-新型冠状病毒感染疾病（COVID-19）的影响分析

  • 经济影响
  • 新型冠状病毒感染疾病（COVID-19）的流行病学
  • 对需求和供给的影响

第5章2018-2030年全球骨髓增生性肿瘤（MPN）治疗市场（依疾病类型）

  • 原发性血小板增多症（ET）
  • 骨髓纤维化（MF）
  • 真性多血症(PV)

第6章2018-2030 年全球骨髓增生性肿瘤 (MPN) 治疗市场（依药物类别）

  • 酪胺酸激化酵素抑制剂
  • Janus激化酵素抑制剂
  • 拮抗
  • 其他的

第7章全球骨髓增生性肿瘤 (MPN) 治疗市场（依配销通路），2018-2030 年

  • 医院药房
  • 零售药房
  • 线上药房

第8章2018-2030年全球骨髓增生性肿瘤（MPN）治疗市场（按地区）

  • 北美洲
  • 美国
  • 加拿大
  • 欧洲
  • 英国
  • 德国
  • 义大利
  • 法国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 中国
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中东
  • GCC
  • 以色列
  • 其他中东地区
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章竞争形势

  • 公司简介
    • Novartis AG
    • PharmaEssentia Corporation
    • Bristol Myers Squibb
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Incyte
    • Johnson &Johnson
    • Teva Pharmaceutical Industries Ltd
    • F. Hoffmann-La Roche AG
    • Gamida Cell
    • Sierra Oncology, Inc
    • CTI BioPharma Corp
    • Imago BioSciences
    • AbbVie Inc
    • Constellation Pharmaceuticals

第10章章

  • 参考
  • 调查方法
简介目录
Product Code: CMI930

The Global Myeloproliferative Neoplasms Treatment Market is estimated to be valued at US$ 9.4 Billion in 2023 and is expected to exhibit a CAGR of 3.9% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 9.4 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 3.90% 2030 Value Projection: US$ 12.28 Bn
Figure 1. Global Myeloproliferative Neoplasms Treatment Market Share (%), By Disease Type, 2023
Myeloproliferative Neoplasms Treatment Market - IMG1

Myeloproliferative neoplasms are a group of rare disorders of the bone marrow that cause an increase in the number of blood cells. The symptoms associated with Myeloproliferative Neoplasms include frequent headaches, tiredness, bruising or unusual bleeding, problem with eyes - such as blurred vision, ringing in the ears, getting more infectious than usual. Moreover, the diagnosis involves blood test to diagnose myeloproliferative neoplasms, the blood tests show the number of blood cells, and can look for genetic mutations. Also, there are other test which done like a bone marrow test, an ultrasound of abdomen.

Different myeloproliferative disorders affect different blood cells that form in the bone marrow. The bone marrow is the soft inner part of bones that makes the blood cells. There are number of different types of myeloproliferative disorders exist, which are;

  • Chronic myeloid leukaemia (CML)
  • Polycythaemia vera
  • Essential thrombocythaemia
  • Primary myelofibrosis

Market Dynamics

The key players in the myeloproliferative neoplasm treatment industry are focusing on research and development to develop innovative treatment for myeloproliferative neoplasm. Thus, an increase in research and developement activities in the market is expected to drive the global myeloproliferative neoplasms treatement market growth over the forecast period. For instance, on February 23, 2023, PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced that the first patient is now being dosed in a phase 2b clinical study evaluating ropeginterferon alfa-2b-njft for the treatment of adults with essential thrombocythemia (ET). BESREMi (ropeginterferon alfa-2b-njft) is innovative monopegylated, long-acting interferon. With its unique pegylation technology, BESREMi has a long duration of activity in the body and is aimed to be administered once every two weeks (or every four weeks with hematological stability for at least one year), allowing flexible dosing that helps meet the individual needs of patients.

Key features of the study:

  • This report provides an in-depth analysis of the global myeloproliferative neoplasms treatment market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year. It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global myeloproliferative neoplasms treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Novartis AG, PharmaEssentia Corporation, Bristol Myers Squibb, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Incyte, Johnson & Johnson, Teva Pharmaceutical Industries Ltd, F. Hoffmann-La Roche AG, Gamida Cell, Sierra Oncology, Inc, CTI BioPharma Corp, Imago BioSciences, AbbVie Inc, and Constellation Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global myeloproliferative neoplasms treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global myeloproliferative neoplasms treatment

Detailed Segmentation:

  • By Disease Type:
    • Essential Thrombocythemia (ET)
    • Myelofibrosis (MF)
    • Polycythemia Vera (PV)
  • By Drug Class:
    • Tyrosine Kinase Inhibitors
    • Janus kinase inhibitors (JAKi)
    • Antimetabolites
    • Others (alkylating agents, etc.)
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles
    • Novartis AG
    • PharmaEssentia Corporation
    • Bristol Myers Squibb
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Incyte
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd,
    • F. Hoffmann-La Roche AG
    • Gamida Cell
    • Sierra Oncology, Inc
    • CTI BioPharma Corp
    • Imago BioSciences
    • AbbVie Inc
    • Constellation Pharmaceuticals

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Disease Type
    • Market Snippet, By Drug Class
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Regulatory Scenario
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Myeloproliferative Neoplasms Treatment Market - COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Myeloproliferative Neoplasms Treatment Market, By Disease Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Essential Thrombocythemia (ET)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Myelofibrosis (MF)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Polycythemia Vera (PV)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

6. Global Myeloproliferative Neoplasms Treatment Market, By Drug Class, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Tyrosine Kinase Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Janus Kinase Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Antimetabolites
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

7. Global Myeloproliferative Neoplasms Treatment Market, By Distribution Channel, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global Myeloproliferative Neoplasms Treatment Market, By Region, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, Y-o-Y Growth and By Disease Type, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Region/Country, 2018 -2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • Novartis AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • PharmaEssentia Corporation
    • Bristol Myers Squibb
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Incyte
    • Johnson & Johnson
    • Teva Pharmaceutical Industries Ltd
    • F. Hoffmann-La Roche AG
    • Gamida Cell
    • Sierra Oncology, Inc
    • CTI BioPharma Corp
    • Imago BioSciences
    • AbbVie Inc
    • Constellation Pharmaceuticals

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact